MOREPENLAB.NS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 10:35):

Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India...

Stats
Šios dienos apimtis	2.04M
Vidutinė apimtis	6.15M
Rinkos kapitalizacija	25.97B
EPS	INR0 ( 2024-04-12 )
Kita pelno data	( INR0 ) 2024-04-30
Last Dividend	INR0.600 ( 2002-09-18 )
Next Dividend	INR0 ( N/A )
P/E	33.87
ATR14	INR0.0530 (0.10%)

Tūris Koreliacija

Ilgas: 0.01 (neutral)

Trumpas: 0.28 (neutral)

Signal:(58.007) Neutral

Morepen Laboratories Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Morepen Laboratories Koreliacija - Valiuta/Žaliavos

-0.01
( neutral )

-0.03
( neutral )

0.00
( neutral )

0.24
( neutral )

0.28
( neutral )

-0.43
( neutral )

Morepen Laboratories Finansinės ataskaitos

Annual	2022
Pajamos:	INR14.18B
Bruto pelnas:	INR4.62B (32.58 %)
EPS:	INR0.770

FY	2022
Pajamos:	INR14.18B
Bruto pelnas:	INR4.62B (32.58 %)
EPS:	INR0.770

FY	2022
Pajamos:	INR15.42B
Bruto pelnas:	INR4.81B (31.18 %)
EPS:	INR2.26

FY	2021
Pajamos:	INR11.75B
Bruto pelnas:	INR3.89B (33.06 %)
EPS:	INR2.16

Financial Reports:

No articles found.

Morepen Laboratories Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Morepen Laboratories Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 2.95 - low (50.00%) | Divividend Growth Potential Score: 3.51 - No dividend growth expected in the near future

Information

First Dividend	INR0.600	2000-04-28
Last Dividend	INR0.600	2002-09-18
Next Dividend	INR0	N/A
Payout Date	2002-10-08
Next Payout Date	N/A
# dividends	5	--
Total Paid Out	INR2.00	--
Avg. Dividend % Per Year	0.00%	--
Score	1.52	--
Div. Sustainability Score	2.95
Div.Growth Potential Score	3.51
Div. Directional Score	3.23	--

Next Divdend (Est)
(2024-07-15)

INR0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

1.52

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2000	INR0	0.00%
2001	INR0	0.00%
2002	INR0	0.00%
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0	0.00%
2019	INR0	0.00%
2020	INR0	0.00%
2021	INR0	0.00%
2022	INR0	0.00%
2023	INR0	0.00%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
TATACONSUM.NS	Dividend Junior	2023-05-19	Annually	26	0.60%
NIPPOBATRY.NS	Dividend Junior	2023-09-20	Annually	23	1.06%
INDIANB.NS	Dividend Junior	2023-06-12	Annually	18	1.99%
CIPLA.NS	Dividend Junior	2023-07-20	Annually	28	0.41%
SANGHVIMOV.NS	Dividend Junior	2023-08-04	Sporadic	18	0.41%
M&MFIN.NS	Dividend Junior	2023-07-20	Annually	19	1.20%
GLOBUSSPR.NS	Dividend Junior	2023-07-14	Sporadic	15	0.36%
ASTEC.NS	No Dividend Player	2023-07-20	Annually	15	0.08%
TIPSINDLTD.NS	Dividend Junior	2023-08-03	Annually	17	0.03%
PEL.NS	Dividend Junior	2023-06-16	Annually	29	1.59%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0467	1.500	9.07	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.0988	1.500	-0.0137	-0.0206	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	31.04	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	1.206	2.00	9.60	10.00	[0 - 30]
freeCashFlowPerShareTTM	1.206	2.00	9.40	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.359	1.000	7.36	7.36	[0.2 - 0.8]
operatingProfitMarginTTM	0.0661	1.000	-0.678	-0.678	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				2.95

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	34.38	1.000	6.63	0	[1 - 100]
returnOnEquityTTM	0.0988	2.50	-0.00883	-0.0206	[0.1 - 1.5]
freeCashFlowPerShareTTM	1.206	2.00	9.60	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	1.206	2.00	9.60	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	7.43	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0378	1.000	-1.555	0	[0.1 - 0.5]
Total Score				3.51

Morepen Laboratories

Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India. The company offers APIs for anti-histaminic, anti-asthmatic, anti-hypercholesterolemic, anti-hypertensive, and anti-diabetic drugs; point of care and medical devices; and home diagnostic products, such as air purifiers, thermometers, stethoscopes, blood pressure monitors, pulse-oximeters, nebulizers, glucometers, strips, sanitizers, disinfectant solutions, masks and gloves, and others. It also provides Burnol, a burn cream; Lemolate for cough and cold; and Fiber-X, a sat isabgol; and formulations for gastro, antibiotics, vitamins, nutritional, and anti-diabetics, as well as cardiac. In addition, the company is involved in the product contract manufacturing and brand sharing businesses; and provision of over-the-counter products under the Dr. Morepen brand. It exports its products to approximately 75 countries. Morepen Laboratories Limited was incorporated in 1984 and is based in New Delhi, India.

Realaus laiko atnaujinimai Morepen Laboratories [MOREPENLAB.NS]

Upcoming Earnings Alert

Morepen Laboratories Dividend Information - Ex Dividend Junior

Dividend Commentary

Top 10 dividend Companies for NSE

Dividend Sustainability Score (DSS)

Dividend Growth Score (DGS)